Charles River Laboratories International Management
Management criteria checks 2/4
Charles River Laboratories International's CEO is Jim Foster, appointed in Jan 1992, has a tenure of 33.67 years. total yearly compensation is $13.47M, comprised of 11.2% salary and 88.8% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth $38.96M. The average tenure of the management team and the board of directors is 5 years and 2.8 years respectively.
Key information
Jim Foster
Chief executive officer
US$13.5m
Total compensation
| CEO salary percentage | 11.23% |
| CEO tenure | 33.7yrs |
| CEO ownership | 0.5% |
| Management average tenure | 5yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Charles River Laboratories International, Inc.'s (NYSE:CRL) Low P/S No Reason For Excitement
Sep 09
Charles River: Margin Fears Outweigh Solid Q2
Aug 06A Look At The Fair Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
Aug 04Is Charles River Laboratories International (NYSE:CRL) Using Too Much Debt?
Jul 17There's No Escaping Charles River Laboratories International, Inc.'s (NYSE:CRL) Muted Revenues Despite A 25% Share Price Rise
May 24We Think Charles River Laboratories International, Inc.'s (NYSE:CRL) CEO Compensation Package Needs To Be Put Under A Microscope
May 14Charles River Faces Significant Regulatory And Macro Pressures
Apr 11Revenues Working Against Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Following 30% Dive
Apr 09Should You Investigate Charles River Laboratories International, Inc. (NYSE:CRL) At US$171?
Mar 13Charles River Laboratories International's (NYSE:CRL) Soft Earnings Are Actually Better Than They Appear
Feb 26Charles River Laboratories International, Inc. (NYSE:CRL) Shares Could Be 39% Below Their Intrinsic Value Estimate
Feb 10Charles River Laboratories: Retained Earnings, ROE, And Debt Management Will Shape Its Future Amid Weak Demand
Feb 01We Think Charles River Laboratories International (NYSE:CRL) Is Taking Some Risk With Its Debt
Jan 26Charles River Labs: Near A Fundamental Trough, Growth Should Reignite Again
Jan 17What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Jan 10Is There Now An Opportunity In Charles River Laboratories International, Inc. (NYSE:CRL)?
Dec 11Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle
Nov 19Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 26What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You
Oct 11
Cost Efficiency And Digital Strategy Propel Earnings Amidst Pharma Industry Challenges
Initiatives for cost efficiency and operational restructuring, including staff reductions, aim to boost net margins through significant annualized savings.Charles River Laboratories: Q2, Cost Structure Streamlining (Rating Upgrade)
Aug 10Charles River Laboratories: Fair Valuation Against Fundamentals
May 31Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 28 2025 | n/a | n/a | -US$69m |
| Mar 29 2025 | n/a | n/a | -US$32m |
| Dec 28 2024 | n/a | n/a | US$10m |
| Sep 28 2024 | n/a | n/a | US$413m |
| Jun 29 2024 | n/a | n/a | US$432m |
| Mar 30 2024 | n/a | n/a | US$439m |
| Dec 30 2023 | n/a | n/a | US$475m |
| Sep 30 2023 | n/a | n/a | US$475m |
| Jul 01 2023 | n/a | n/a | US$484m |
| Apr 01 2023 | n/a | n/a | US$496m |
| Dec 31 2022 | US$13m | US$1m | US$486m |
| Sep 24 2022 | n/a | n/a | US$436m |
| Jun 25 2022 | n/a | n/a | US$443m |
| Mar 26 2022 | n/a | n/a | US$422m |
| Dec 25 2021 | US$14m | US$1m | US$391m |
| Sep 25 2021 | n/a | n/a | US$397m |
| Jun 26 2021 | n/a | n/a | US$396m |
| Mar 27 2021 | n/a | n/a | US$375m |
| Dec 26 2020 | US$13m | US$1m | US$364m |
| Sep 26 2020 | n/a | n/a | US$301m |
| Jun 27 2020 | n/a | n/a | US$271m |
| Mar 28 2020 | n/a | n/a | US$248m |
| Dec 28 2019 | US$18m | US$1m | US$252m |
| Sep 28 2019 | n/a | n/a | US$231m |
| Jun 29 2019 | n/a | n/a | US$219m |
| Mar 30 2019 | n/a | n/a | US$227m |
| Dec 29 2018 | US$14m | US$1m | US$225m |
Compensation vs Market: Jim's total compensation ($USD13.47M) is above average for companies of similar size in the US market ($USD8.51M).
Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.
CEO
Jim Foster (74 yo)
Mr. James C. Foster, J.D. has been the Chairman of the Board at Charles River Laboratories International, Inc. since 2000 and has been its President and Chief Executive Officer since 1992. Mr. Foster joine...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 33.7yrs | US$13.47m | 0.51% $ 39.0m | |
| Corporate Executive VP & CFO | 3.3yrs | US$3.15m | 0.014% $ 1.1m | |
| Corporate Executive VP & COO | 3.8yrs | US$5.06m | 0.098% $ 7.5m | |
| Corporate Executive Vice President of Corporate Development & Strategy | 14.7yrs | US$2.98m | 0.015% $ 1.2m | |
| Corporate Executive VP & Chief People Officer | 6.7yrs | US$2.81m | 0.027% $ 2.1m | |
| Corporate Senior VP & Chief Accounting Officer | 8.4yrs | no data | 0.014% $ 1.1m | |
| Corporate Senior VP & Chief Scientific Officer | 3.8yrs | no data | no data | |
| Corporate EVP | 4.3yrs | no data | 0.0042% $ 322.0k | |
| Corporate Vice President of Investor Relations | no data | no data | no data | |
| Corporate Senior VP | 5yrs | no data | no data | |
| Corporate Senior Vice President | no data | no data | no data | |
| Corporate Senior Vice President of European Safety Assessment | no data | no data | no data |
Experienced Management: CRL's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 36.7yrs | US$13.47m | 0.51% $ 39.0m | |
| Director | less than a year | no data | no data | |
| Independent Director | 5.9yrs | US$345.50k | 0.0081% $ 616.4k | |
| Independent Director | 2.8yrs | US$320.50k | 0.0030% $ 227.9k | |
| Lead Independent Director | 8.2yrs | US$340.50k | 0.025% $ 1.9m | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data | |
| Independent Director | 5.6yrs | US$340.50k | 0.0061% $ 468.8k | |
| Director | less than a year | no data | no data | |
| Independent Director | 4.9yrs | US$325.50k | 0.0068% $ 520.0k | |
| Independent Director | 1.7yrs | US$413.98k | 0.0021% $ 157.5k |
Experienced Board: CRL's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/22 18:58 |
| End of Day Share Price | 2025/09/22 00:00 |
| Earnings | 2025/06/28 |
| Annual Earnings | 2024/12/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Charles River Laboratories International, Inc. is covered by 43 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Gregory Bolan | Avondale Partners |
| Eric Coldwell | Baird |